Novel mouse model for evaluating in vivo efficacy of xCT inhibitor
xCT, a well-known cystine transporter, is reported to be involved in the proliferation of various cells, such as cancer cells, immune cells, and fibroblasts. xCT inhibitor is expected to be a promising drug for cancer or immune diseases. However, there are little studies reporting that xCT inhibitor...
Main Authors: | Ryosuke Yoshioka, Yusuke Fujieda, Yamato Suzuki, Osamu Kanno, Asako Nagahira, Tomohiro Honda, Masao Murakawa, Hiroshi Yukiura |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-07-01
|
Series: | Journal of Pharmacological Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861319356889 |
Similar Items
-
Role of SLC7A11/xCT in Ovarian Cancer
by: Sonia Fantone, et al.
Published: (2024-01-01) -
Decreased xCT activity in patients associated with Helicobacter pylori infection
by: Ling Wang, et al.
Published: (2022-12-01) -
Functional analysis of CD44 variants and xCT in canine tumours
by: Atsushi Tanabe, et al.
Published: (2021-03-01) -
xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner
by: Keiko Miyamoto, et al.
Published: (2020-03-01) -
Genomic analysis of xCT-regulatory network in KSHV+ primary effusion lymphomas
by: Zhiqiang Qin, et al.
Published: (2016-06-01)